{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:52Z","timestamp":1787162632330,"version":"build-2736575974"},"reference-count":95,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/wnf.0b013e31815cba78","type":"journal-article","created":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T03:11:17Z","timestamp":1227496277000},"page":"319-332","source":"Crossref","is-referenced-by-count":19,"title":["Antipsychotic Polypharmacy in Patients With Schizophrenia in a Brief Hospitalization Unit"],"prefix":"10.1097","volume":"31","author":[{"given":"Ivan","family":"Lerma-Carrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"de Pablo Br\u00fchlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Leonor","family":"del Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pascual-Pinazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Baca-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R2-2-20210203","first-page":"1","article-title":"American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition.","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"3","key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/oxfordjournals.schbul.a007111","article-title":"The Texas medication algorithm project: clinical results for schizophrenia.","volume":"30","author":"Miller","year":"2004","journal-title":"Schizophr Bull"},{"issue":"2","key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.","volume":"30","author":"Lehman","year":"2004","journal-title":"Schizophr Bull"},{"issue":"3","key":"R6-2-20210203","first-page":"157","article-title":"Prescribing patterns of neuroactive drugs in 98 schizophrenic patients.","volume":"26","author":"Heresco-Levy","year":"1989","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"5","key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2125.1995.tb05791.x","article-title":"Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.","volume":"40","author":"Kiivet","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF00787922","article-title":"Psychotropic drug prescription in rehabilitation. A survey in Hong Kong.","volume":"31","author":"Ungvari","year":"1996","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"suppl","key":"R9-2-20210203","first-page":"S35","article-title":"A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia.","volume":"53","author":"Ito","year":"1999","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0924-9338(99)80713-5","article-title":"Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics.","volume":"14","author":"Rittmannsberger","year":"1999","journal-title":"Eur Psychiatry"},{"issue":"2","key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/oxfordjournals.schbul.a033465","article-title":"Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders.","volume":"26","author":"Wang","year":"2000","journal-title":"Schizophr Bull"},{"issue":"1","key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1365-2125.2000.00108.x","article-title":"Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists.","volume":"49","author":"Fourrier","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/070674370104600404","article-title":"Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.","volume":"46","author":"Procyshyn","year":"2001","journal-title":"Can J Psychiatry"},{"issue":"1","key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.schbul.a006924","article-title":"Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region.","volume":"28","author":"Weissman","year":"2002","journal-title":"Schizophr Bull"},{"issue":"1","key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.schbul.a006920","article-title":"Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.","volume":"28","author":"Covell","year":"2002","journal-title":"Schizophr Bull"},{"issue":"1","key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a006928","article-title":"Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.","volume":"28","author":"Clark","year":"2002","journal-title":"Schizophr Bull"},{"issue":"9","key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"984","DOI":"10.4088\/JCP.v64n0902","article-title":"Polypharmacy in patients with schizophrenia.","volume":"64","author":"McCue","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"R18-2-20210203","first-page":"333","article-title":"Polipharmacy in the antipsychotic prescribing in practices psychiatric out-patient clinic.","volume":"32","author":"Florez Menendez","year":"2004","journal-title":"Actas Esp Psiquiatr"},{"issue":"10","key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.","volume":"65","author":"Ganguly","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2125.2004.02102.x","article-title":"Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.","volume":"58","author":"Sim","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/oxfordjournals.schbul.a007117","article-title":"Validation of polypharmacy process measures in inpatient schizophrenia care.","volume":"30","author":"Janssen","year":"2004","journal-title":"Schizophr Bull"},{"issue":"1","key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","article-title":"Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.","volume":"5","author":"Faries","year":"2005","journal-title":"BMC Psychiatry"},{"key":"R23-2-20210203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1192\/bjp.187.3.243","article-title":"Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription.","volume":"187","author":"Ito","year":"2005","journal-title":"Br J Psychiatry"},{"key":"R24-2-20210203","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine a double-blind placebo-controlled study.","volume":"171","author":"Shiloh","year":"1997","journal-title":"Br J Psychiatry"},{"issue":"1","key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4088\/JCP.v66n0109","article-title":"A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.","volume":"66","author":"Anil Yagcioglu","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia.","volume":"354","author":"Honer","year":"2006","journal-title":"N Engl J Med"},{"key":"R28-2-20210203","first-page":"395","article-title":"Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.","volume":"57","author":"Henderson","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0920-9964(00)00104-3","article-title":"An open trial of risperidone augmentation of partial response to clozapine.","volume":"48","author":"Taylor","year":"2001","journal-title":"Schizophr Res"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4088\/JCP.v62n0210f","article-title":"Addition of risperidone to clozapine therapy in chronically psychotic impatiens.","volume":"62","author":"De Groot","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1176\/appi.ajp.161.5.924-a","article-title":"Clozapine combined with amisulpride for refractory schizophrenia.","volume":"161","author":"Agelink","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R32-2-20210203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0447.2004.00356.x","article-title":"Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially response to clozapine.","volume":"110","author":"Munro","year":"2004","journal-title":"Acta Psychiatr Scand"},{"key":"R33-2-20210203","first-page":"17","article-title":"Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: an open clinical study.","volume":"9","author":"Ziegenbein","year":"2006","journal-title":"German J Psychiatry"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4088\/JCP.v64n0215b","article-title":"Ziprasidone augmentation of clozapine in 11 patients.","volume":"64","author":"Kaye","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.wnf.0000183446.58529.30","article-title":"Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study.","volume":"28","author":"Ziengenbein","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00044011-200626030-00001","article-title":"Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation.","volume":"26","author":"Ziegenbein","year":"2006","journal-title":"Clin Drug Invest"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00004714-200010000-00002","article-title":"Olanzapine and sulpiride: a preliminary study of combination\/augmentation in patients with treatment-resistant schizophrenia.","volume":"20","author":"Raskin","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200401000-00004","article-title":"Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.","volume":"19","author":"Kotler","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"R40-2-20210203","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1176\/ajp.152.9.1401b","article-title":"Pharmacokinetic interaction between risperidone and clozapine.","volume":"152","author":"Tyson","year":"1995","journal-title":"Am J Psychiatry"},{"key":"R42-2-20210203","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0447.1999.tb07230.x","article-title":"Risperidone and clozapine combination for treatment of refractory schizophrenia.","volume":"99","author":"Morera","year":"1999","journal-title":"Acta Psychiatr Scand"},{"key":"R44-2-20210203","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/j.1440-1614.2000.0751j.x","article-title":"Adjunctive risperidone treatment in patients with \"clozapine-resistant schizophrenia\".","volume":"34","author":"Adesanya","year":"2000","journal-title":"Aust NZ J Psychiatry"},{"key":"R45-2-20210203","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1046\/j.1440-1614.2001.0911d.x","article-title":"Clozapine-risperidone combination in treatment-resistant schizophrenia.","volume":"35","author":"Raju Kumar","year":"2001","journal-title":"Aust NZ J Psychiatry"},{"key":"R46-2-20210203","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1600-0447.2000.tb10935.x","article-title":"Clozapine and risperidone: combination\/augmentation treatment of refractory schizophrenia: a preliminary observation.","volume":"101","author":"Raskin","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"R47-2-20210203","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-979590","article-title":"Risperidone augmentation of clozapine.","volume":"28","author":"McCartthy","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"R48-2-20210203","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/070674379604100511","article-title":"Hoarding and clozapine-risperidone combination.","volume":"41","author":"Chong","year":"1996","journal-title":"Can J Psychiatry"},{"key":"R49-2-20210203","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1176\/ajp.154.4.543","article-title":"Chronic schizophrenia: response to clozapine, risperidone and paroxetine.","volume":"154","author":"Patel","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"suppl 2","key":"R50-2-20210203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0924-977X(98)80398-2","article-title":"Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia.","volume":"8","author":"Mantonakis","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"R51-2-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.wnf.0000240947.51994.96","article-title":"Adjunctive treatment with risperidone in clozapine resistant schizophrenia: a case report and review.","volume":"30","author":"Lerma-Carrillo","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"R52-2-20210203","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10401239809148944","article-title":"Olanzapine augmentation of clozapine.","volume":"10","author":"Gupta","year":"1998","journal-title":"Ann Clin Psychiatry"},{"key":"R53-2-20210203","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4088\/JCP.v61n0914e","article-title":"Polypharmacy of two atypical antipsychotics.","volume":"61","author":"Rhoads","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R54-2-20210203","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-2003-814821","article-title":"Ziprasidone-augmentation of clozapine.","volume":"31","author":"Zink","year":"2004","journal-title":"Psychiatr Prax"},{"key":"R55-2-20210203","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hup.580","article-title":"Combination of ziprasidone and clozapine in treatment resistant schizophrenia.","volume":"19","author":"Zink","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"R56-2-20210203","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1176\/jnp.2006.18.2.246","article-title":"Cloapine nad Ziprasidone: A useful combination in patients with treatment-resistant schizophrenia.","volume":"18","author":"Ziegenbein","year":"2006","journal-title":"J Neuropsychitr Clin Neurosci"},{"issue":"suppl","key":"R60-2-20210203","first-page":"209","article-title":"Amisulpride augmentation of clozapine effect in patients with treatment resistant schizophrenia.","volume":"53","author":"Matthiasson","year":"2002","journal-title":"Schizophr Res"},{"key":"R61-2-20210203","first-page":"128","article-title":"Saving potential of clozapine due to combination with amisulpride.","volume":"8","author":"Croissant","year":"2001","journal-title":"Psychopharmakotherapie"},{"issue":"suppl 1","key":"R62-2-20210203","first-page":"311S","article-title":"Clozapine combined with amisulpride in the treatment refractory schizophrenia.","volume":"2","author":"Agelink","year":"2001","journal-title":"World J Biol Psychiatry"},{"issue":"suppl 1","key":"R63-2-20210203","doi-asserted-by":"crossref","first-page":"99S","DOI":"10.1016\/S0924-9338(02)80449-7","article-title":"Coadministration of clozapine and amisulpride in psychotic patients.","volume":"17","author":"Ziegenben","year":"2002","journal-title":"Eur Psychiatry"},{"key":"R64-2-20210203","first-page":"48S","article-title":"Coadministration of clozapine and amisulpride in patients with schizophrenia.","volume":"53","author":"Ziegenben","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R65-2-20210203","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1039-8562.2003.02064.x","article-title":"Combined use of amisulpride and clozapine for patients with treatment resistant schizophrenia.","volume":"12","author":"Cook","year":"2004","journal-title":"Australas Psychiatry"},{"key":"R66-2-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2004-815471","article-title":"Combination of clozapine and amisulpride in treatment-resistant schizophrenia schizophrenia-case reports and review of the literature.","volume":"37","author":"Zink","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R67-2-20210203","first-page":"64","article-title":"Amisulpride in addition to clozapine: a retrospective study indicates improved efficacy and good tolerability.","volume":"6","author":"Kampf","year":"2003","journal-title":"German J Psychiatry"},{"key":"R68-2-20210203","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-2005-837772","article-title":"Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms.","volume":"38-","author":"Kampf","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"R69-2-20210203","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-2005-837771","article-title":"Reduction of side effects by combining clozapine with amisulpride: case review and short review of clozapine-induced hypersalivation. A case report.","volume":"38","author":"Croissant","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"R70-2-20210203","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.4088\/JCP.v65n0918d","article-title":"Possible increased efficacy of low-dose clozapine when combined with aripiprazole.","volume":"65","author":"Lim","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R71-2-20210203","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4088\/JCP.v66n0318c","article-title":"Increased efficacy with addition of clozapine to aripiprazole.","volume":"66","author":"DeQuardo","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R72-2-20210203","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/j.1440-1614.2005.01688_2.x","article-title":"Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia.","volume":"39","author":"Ziegenbein","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"key":"R73-2-20210203","first-page":"82","article-title":"Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?","volume":"191","author":"Karunakanan","year":"2007","journal-title":"J Psychopharmacol"},{"key":"R74-2-20210203","doi-asserted-by":"crossref","first-page":"675","DOI":"10.4088\/JCP.v67n0420d","article-title":"Clozapine augmentation for negative symptoms.","volume":"67","author":"Clarke","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R75-2-20210203","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.pnpbp.2006.03.024","article-title":"Benefits of combining aripiprazole to clozapine.","volume":"30","author":"Rocha","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R76-2-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.eurpsy.2003.09.002","article-title":"Combination of amisulpride and olanzapine in treatment resistant schizophrenic psychoses.","volume":"19","author":"Zink","year":"2004","journal-title":"Eur Psychiatry"},{"key":"R77-2-20210203","first-page":"409","article-title":"Augmentation of olanzapine in treatment-resistant schizophrenia.","volume":"30","author":"Zink","year":"2005","journal-title":"J Psychiatr Neurosci"},{"issue":"suppl 1","key":"R78-2-20210203","first-page":"S76","article-title":"Combination of olanzapine and amisulpride in treatment resistant schizophrenic psychoses.","volume":"5","author":"Thome","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"R79-2-20210203","first-page":"729","article-title":"Incompatibility of olanzapine and amisulpride in multisystematic myotonic myopathy.","volume":"72","author":"Pedrosa Gil","year":"2001","journal-title":"Nervenartz"},{"key":"R80-2-20210203","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00002826-200009000-00009","article-title":"Combined use of risperidone and olanzapine in treatment of patients with resistant schizophrenia: a preliminary case series report.","volume":"23","author":"Lerner","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"suppl 2","key":"R81-2-20210203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0924-977X(98)80398-2","article-title":"Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia.","volume":"8","author":"Mantonakis","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"key":"R82-2-20210203","first-page":"86","article-title":"Combination risperidone and quetiapine therapy in refractory schizophrenia.","volume":"46","author":"Chue","year":"2001","journal-title":"Can J Psychiatry"},{"key":"R83-2-20210203","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/070674370304800617","article-title":"Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia.","volume":"48","author":"Bozikas","year":"2003","journal-title":"Can J Psychiatry"},{"key":"R84-2-20210203","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.wnf.0000159953.41769.d7","article-title":"Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy.","volume":"28","author":"Lerner","year":"2005","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"R85-2-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/070674370404900213","article-title":"Aripiprazole-olanzapine combination for treatment of schizophrenia.","volume":"49","author":"Duggal","year":"2004","journal-title":"Can J Psychiatry"},{"issue":"suppl 1","key":"R86-2-20210203","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2004-828458","article-title":"Risk of QTc prolongation due to combination of ziprasidone and quetiapine.","volume":"31","author":"Minov","year":"2004","journal-title":"Psychiatr Prax"},{"key":"R87-2-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881105048903","article-title":"Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with prolactin secreting pituitary microadenoma.","volume":"19","author":"Dunkley","year":"2005","journal-title":"J Psychopharmacol"},{"key":"R88-2-20210203","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1034\/j.1600-0447.2000.102005390.x","article-title":"Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine.","volume":"102","author":"Stubbs","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"R89-2-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/10401239609147759","article-title":"Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients.","volume":"8","author":"Mowerman","year":"1996","journal-title":"Ann Clin Psychiatry"},{"key":"R90-2-20210203","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4088\/JCP.v60n1019","article-title":"Adding other antipsychotics to clozapine.","volume":"60","author":"Cooke","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R91-2-20210203","first-page":"443","article-title":"Concomitant use of thioridazine with risperidone.","volume":"53","author":"Goos","year":"1995","journal-title":"Am J Health Syst Pharm"},{"key":"R92-2-20210203","first-page":"137","article-title":"Combining risperidone with standard neuroleptics for refractory schizophrenia patients.","volume":"53","author":"Bacher","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R93-2-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1176\/jnp.13.1.114","article-title":"Risperidone addition and psychotic exacerbation.","volume":"13","author":"Terao","year":"2001","journal-title":"J Neuropsychiatr Clin Neurosci"},{"issue":"suppl 3","key":"R94-2-20210203","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0924-977X(00)80292-8","article-title":"A more favorable clinical outcome with sulpiride augmentation in a patient with chronic schizophrenia partially responsive to olanzapine.","volume":"10","author":"Witz","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"R95-2-20210203","first-page":"189","article-title":"Treatment of schizophrenia with antipsychotics in combination.","volume":"44","author":"Waring","year":"1999","journal-title":"Can J Psychiatry"},{"key":"R96-2-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-2007-979185","article-title":"Psychotropic drug prescription in a psychiatric university hospital.","volume":"32","author":"Voirol","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"R97-2-20210203","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-2007-1017445","article-title":"Drug prescribing pattern of a psychiatry university hospital in Germany.","volume":"16","author":"Schmidt","year":"1983","journal-title":"Pharmacopsychiatry"},{"key":"R98-2-20210203","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1192\/bjp.145.5.502","article-title":"A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital.","volume":"145","author":"Edwards","year":"1984","journal-title":"Br J Psychiatry"},{"issue":"suppl 2","key":"R100-2-20210203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004850-199705002-00006","article-title":"Amisulpride: from animal pharmacology to therapeutic action.","volume":"12","author":"Scatton","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"issue":"suppl 1","key":"R101-2-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S1461145704004109","article-title":"Amisulpride: a selective dopamine antagonist and atypical antipsychotic: results of meta-analysis of randomized controlled trials.","volume":"7","author":"Leucht","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R102-2-20210203","first-page":"1112","article-title":"Characteristics of repeatedly assaultive psychiatric inpatients.","volume":"41","author":"Convit","year":"1990","journal-title":"Hosp Commun Psychiatry"},{"key":"R103-2-20210203","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1176\/ps.49.11.1458","article-title":"Repetitively violent patients in psychiatric units.","volume":"49","author":"Owen","year":"1998","journal-title":"Psychiatr Serv"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200811000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T04:15:23Z","timestamp":1684642523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200811000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31815cba78","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}